Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Return on Sales (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Return on Sales data on record, last reported at 3.61% in Q3 2025.

  • For Q3 2025, Return on Sales rose 179.0% year-over-year to 3.61%; the TTM value through Sep 2025 reached 0.2%, up 650.0%, while the annual FY2024 figure was 2.43%, 952.0% up from the prior year.
  • Return on Sales reached 3.61% in Q3 2025 per STOK's latest filing, down from 1.7% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.71% in Q1 2025 and bottomed at 12.37% in Q2 2023.
  • Average Return on Sales over 4 years is 5.91%, with a median of 6.26% recorded in 2024.
  • Peak YoY movement for Return on Sales: tumbled -473bps in 2023, then skyrocketed 916bps in 2024.
  • A 4-year view of Return on Sales shows it stood at 7.86% in 2022, then dropped by -23bps to 9.64% in 2023, then skyrocketed by 95bps to 0.47% in 2024, then plummeted by -663bps to 3.61% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 3.61% in Q3 2025, 1.7% in Q2 2025, and 0.71% in Q1 2025.